Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Fast-track diagnostics releases CE-labelled Real-time PCR kit to detect Zaire Ebolavirus

Fast-track diagnostics, a global leader in the design, development and manufacture of infectious disease detection kits, has released a CE labelled Real-time PCR kit for the detection of the Zaire Ebolavirus – the strain responsible for the current outbreak in West Africa.

8 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

First two patients enrolled in AGA’s GERD Registry successfully undergo treatment

The American Gastroenterological Association (AGA) Center for GI Innovation and Technology is pleased to announce that the first two enrollees in the STAR Registry — which seeks to compare laparoscopic surgery to an incisionless procedure to treat gastroesophageal reflux disease (GERD) — have successfully undergone treatment.

23 Dec 2014

AGA) Center for GI Innovation and Technology is pleased to announce that the first two enrollees in the STAR Registry

23 Dec 2014

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Dec 2014

Mayo Clinic researchers correctly evaluate polyps using high-definition optical lenses

It may not be necessary for experienced gastroenterologists to send polyps they remove from a patient's colon to a pathologist for examination, according to a large study conducted by physician researchers at the Jacksonville campus of Mayo Clinic.

19 Dec 2014

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).

19 Dec 2014

New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

A new study by an international team of researchers shows for the first time that people may inherit some of the intestinal bacteria that cause Crohn's disease and ulcerative colitis, collectively know as inflammatory bowel disease (IBD). The study, recently published in Genome Medicine, also confirmed that antibiotics could worsen the imbalance in the gut microbes.

16 Dec 2014

Scientists validate oral vaccine delivery system to combat global health threats

Scientists at The Forsyth Institute and Tufts University have succeeded in describing and validating a unique system of oral vaccine delivery using a common bacteria found in the mouth.

16 Dec 2014

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

16 Dec 2014

Molecular signaling pathways in the gut influence NAFLD

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and affects approximately 1 billion people worldwide. It is not clear how this disease develops, but recent studies suggest that the bacterial population in the gut influences NAFLD.

15 Dec 2014

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients.

From Evident Corporation - Life Sciences 15 Dec 2014

Abbott acquires control of Veropharm for $305 million

Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer.

12 Dec 2014

Research highlights potential of computers to enhance quality of care, medical outcomes

A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study.

10 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

The American Gastroenterological Association Research Foundation is pleased to announce that Ashish Nimgaonkar, MBBS, MTech, MS, from John Hopkins University, has received the inaugural AGA-Boston Scientific Career Development Technology & Innovation Award. This award is graciously supported by a grant from Boston Scientific, a leading innovator of medical solutions.

5 Dec 2014

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Fast-track diagnostics releases CE-labelled Real-time PCR kit to detect Zaire Ebolavirus

FDA receives Actavis' NDA resubmission for cariprazine

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

First two patients enrolled in AGA’s GERD Registry successfully undergo treatment

AGA) Center for GI Innovation and Technology is pleased to announce that the first two enrollees in the STAR Registry

Oral budesonide suspension offers hope for pediatric patients with EoE

Mayo Clinic researchers correctly evaluate polyps using high-definition optical lenses

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

Scientists validate oral vaccine delivery system to combat global health threats

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

Molecular signaling pathways in the gut influence NAFLD

Olympus receives FDA clearance for Narrow Band Imaging

Abbott acquires control of Veropharm for $305 million

Research highlights potential of computers to enhance quality of care, medical outcomes

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

Pittcon Keynote Speaker Highlights eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Pittcon Keynote Speaker Highlights eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in